Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

Leukemia

Volumn 29, Issue 5, 2015, Pages 1115-1122

  Jawhar, M ^a   Schwaab, J ^a   Schnittger, S ^b   Sotlar, K ^c   Horny, H P ^c   Metzgeroth, G ^a   Muller N ^a   Schneider, S ^a   Naumann, N ^a   Walz, C ^c   Haferlach, T ^b   Valent, P ^d   Hofmann, W K ^a   Cross, N C P ^e,f   Fabarius, A ^a   Reiter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE KIT D816V; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ASXL1 PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN; RIBONUCLEOPROTEIN; SRSF2 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TET2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLONY FORMING UNIT GM; FEMALE; GENE FREQUENCY; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; INDOLENT SYSTEMIC MASTOCYTOSIS; MALE; MIDDLE AGED; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; CELL LINEAGE; CELL SEPARATION; CYTOGENETICS; CYTOLOGY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GENOTYPE; MAST CELL; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; STEM CELL;

AGED; CELL LINEAGE; CELL SEPARATION; CYTOGENETICS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; GENOTYPE; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; REPRESSOR PROTEINS; RIBONUCLEOPROTEINS; STEM CELLS;

EID: 84929289339     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.4     Document Type: Article

References (43)

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625.
2. Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 401-411.
3. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
4. Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180-188.
5. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
6. Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-88.
7. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010; 220: 586-595.
8. Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012; 120: 4846-4849.
9. Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012; 7: e43090.
10. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, P firrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460-2466.
11. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865.
12. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
13. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080-3088.
14. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220-2228.
15. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
16. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118: 1723-1735.
17. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865-2870.
18. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am 2014;34: 239-262.
19. Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012; 148: 873-885.
20. Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nat Biotechnol 2012; 30: 639-647.
21. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 118-149.
22. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
23. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014; 28:1705-1715.
24. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
25. Valent P HH, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM. Mastocytosis. In: Elaine S, Jaffe NLH, Stein Harald, James WV (eds). Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization (WHO) Classification of Tumours vol. 1. IARC Press: Lyon, France, 2001; pp 291-302.
26. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25:543-551.
27. Horny HP AC, Metcalfe DD, Swerdlow SH, Campo E, Harris NL et al. World Health Organization (WHO) Classification of Tumours. Mastocytosis (Mast cell disease). Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues vol. 2. Lyon, France: IARC Press, 2008; pp 54-63.
28. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115:3842-3847.
29. Simons A, Shaffer LG, Hastings RJ. Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 Edition. Cytogenet Genome Res 2013; 141: 1-6.
30. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase- FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
31. Sotlar K. c-Kit mutational analysis in paraf fin material. Methods Mol Biol 2013; 999:59-78.
32. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. J Clin Pathol Mol Pathol 2000; 53: 188-193.
33. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013; 121:2186-2198.
34. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008; 22: 1841-1848.
35. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27:1861-1869.
36. Agis H, Fureder W, Bankl HC, Kundi M, Sperr WR, Willheim M et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology 1996; 87: 535-543.
37. Agis H, Willheim M, Sperr WR, Wilfing A, Kromer E, Kabrna E et al. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol 1993; 151: 4221-4227.
38. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in480% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011; 25 : 877-879.
39. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, Lea NC et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932.
40. Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 2013; 98 : 1058-1066.
41. Tefferi A, Lim KH, Levine R. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 361: 1117-1118.
42. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428-2436.
43. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57: 604-608.